

Attorney Docket No. 175912

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

RECEIVED

AUG 0 8 2001

TECH CENTER 1600/2900

Boyd

Application No. 09/427,873

Examiner: J. Parkin

Group Art Unit: 1648

Filed: October 27, 1999

For:

METHODS OF USING

CYANOVIRINS TO INHIBIT

VIRAL INFECTION

PENDING CLAIMS AS OF AUGUST 3, 2001

20. A method of inhibiting therapeutically or prophylactically a viral infection of a host, which method comprises administering to the host an antiviral effective amount of an isolated and purified antiviral agent selected from the group consisting of an antiviral protein, an antiviral peptide, an antiviral protein conjugate, and an antiviral peptide conjugate, wherein said antiviral protein or antiviral peptide is encoded by an isolated and purified nucleic acid molecule encoding at least nine contiguous amino acids of SEQ ID NO: 2, wherein said at least nine contiguous amino acids of SEQ ID NO: 2 has antiviral activity, whereupon administration of said antiviral effective amount of said antiviral agent, said viral infection of said host is inhibited.

- 21. The method of claim 20, wherein said antiviral protein comprises the amino acid sequence of SEQ ID NO: 2.
- 22. The method of claim 20, wherein said antiviral protein conjugate or said antiviral peptide conjugate comprises (i) at least nine contiguous amino acids of SEQ ID NO: 2, wherein said at least nine contiguous amino acids of SEQ ID NO: 2 has antiviral activity, and (ii) an isolated and purified viral envelope glycoprotein.

In re Appln. of Boyd Application No. 09/427,873

- 23. The method of claim 22, wherein said antiviral protein comprises the amino acid sequence of SEQ ID NO: 2.
- 24. The method of claim 22, wherein said isolated and purified viral envelope glycoprotein is an isolated and purified retroviral envelope glycoprotein.
- 25. The method of claim 24, wherein said isolated and purified retroviral envelope glycoprotein is an isolated and purified immunodeficiency viral envelope glycoprotein.
- 26. The method of claim 25, wherein said isolated and purified immunodeficiency viral envelope glycoprotein is an isolated and purified viral envelope glycoprotein of HIV-1 or HIV-2.
- 27. The method of claim 26, wherein said isolated and purified viral envelope glycoprotein of HIV-1 or HIV-2 comprises gp120.